Redefining Early Stage Investments (RESI) JPM San Francisco
The Redefining Early Stage Investments (RESI) conference series connects start-ups, early-stage investors, and strategic channel partners. RESI maximizes fundraising companies’ efforts to find partners who are a fit for their technology and stage of development. RESI is uniquely cross-border and cross-domain, connecting start-ups with 10 categories of global investors across the silos of drugs, devices, diagnostics, and digital health (4 Ds). RESI caters to both the earliest-stage start-ups, those seeking grants, seed, and angel capital, and the early-stage firms who seek series A and B funding.
If attending, don't miss these NIH-backed companies participating in the Innovator's Pitch Challenge. The companies below all received early-stage, non-dilutive small business funding (SBIR/STTR).
| AdviNow (NIH-sponsored at this event) | 1/10 at 1 p.m. PST, Session 4 - Medical Device & Digital Health |
| Blue Marble Health | 1/10 at 4 p.m. PST, Session 14 - Therapeutics & Digital Health |
| Hemex Health (NIH-sponsored at this event) | 1/10 at 11 a.m. PST, Session 10 - Diagnostics |
| Opticyte, Inc. | 1/10 at 11 a.m. PST, Session 3 - Medical Devices |
| Regenosine, Inc. (NIH-sponsored at this event) | 1/10 at 10 a.m. PST, Session 2 - Therapeutics |
| Samay Health (formerly known as Respira Labs) | 1/10 at 10 a.m. PST, Session 9 - Medical Devices |
| Vasculonics, Inc. (NIH-sponsored at this event) | 1/10 at 10 a.m. PST, Session 2 - Therapeutics |
| Wildflower Biopharma, Inc. (NIH-sponsored at this event) | 1/10 at 10 a.m. PST, Session 2 - Therapeutics |
